An updated 2026 Cochrane review has examined whether cannabis-based medicines relieve chronic neuropathic pain in adults. It updates the 2018 version and includes 21 randomized, double-blind trials with 2187 participants. Twenty trials compared a cannabis-based medicine with placebo; one used dihydrocodeine as the comparator. So the review is not entirely placebo-controlled.
The review looked at pain relief of at least 50% for three types of medicines. For THC-dominant medicines, the risk difference versus placebo was 0.14 (95% CI -0.07 to 0.37; 7 studies, 534 participants). For balanced THC/CBD medicines, it was 0.04 (95% CI 0.00 to 0.08; 8 studies, 746 participants). For CBD-dominant medicines, it was -0.08 (95% CI -0.20 to 0.05; 5 studies, 208 participants). All were very low-certainty evidence. The authors conclude there is no clear evidence for an effect on at least 50% pain relief.
The confidence in these results is very low. Results varied between studies, and some methods were unclear. Fourteen of the 21 included trials had pharmaceutical-company funding; the review itself reports no funding. Follow-up lasted only 2 to 26 weeks, and people with serious internal disease were excluded. These limitations mean the evidence cannot rule out benefit or harm.
The review assessed adverse events separately. Uncertainty about pain relief should not be read as evidence of safety.
Study card: updated Cochrane systematic review and meta-analysis; 21 randomized, double-blind trials, 2,187 participants, two to 26 weeks. Risk of bias was low in six trials, unclear in ten and high in five. The substantial-pain-relief comparison for each formulation was rated very low certainty.
Source: Ateş G et al. Cochrane Database Syst Rev. 2026;1:CD012182. PMID 41548880. DOI 10.1002/14651858.CD012182.pub3. https://pubmed.ncbi.nlm.nih.gov/41548880/
2026 Cochrane plain-language summary: https://www.cochrane.org/evidence/CD012182_what-are-benefits-and-risks-cannabis-based-medicines-adults-chronic-neuropathic-pain
Figure: Three separate risk-difference intervals for at least 50% pain relief, each versus placebo. The zero line denotes no difference; all three comparisons are rated very low certainty. Values and limitations are also stated in the text.
Escribir Únete para participar en la discusión.